The Role of Selected Adipokines and Ghrelin in the Prognosis After Myocardial Infarction in a 12-month Follow-up in the Presence of Metabolic Syndrome

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2017 Jul 20

PMID 28721146

Citations 7

Authors

Blazej Michalski

Ewa Szymczyk

Lukasz Peczek

Barbara Nawrot

Karolina Kupczynska

Maria Krzeminska-Pakula

Jan Z Peruga

Piotr Lipiec

Jaroslaw D Kasprzak

Affiliations

Soon will be listed here.

Abstract

Introduction: The aim of this study was to evaluate the predictive value of selected adipokines in the improvement in the ejection fraction and in the development of adverse cardiac remodeling during 12 months of follow-up among patients with an ST-segment elevation acute myocardial infarction (STEMI) in the presence of metabolic syndrome (MeS).

Material And Methods: The study population consisted of 69 patients (49 male; mean age: 59 ±10 years) with a first STEMI that was treated with a primary percutaneous coronary intervention (pPCI). In this group, 36 patients (18 male; mean age: 60 ±15 years) had MeS according to the definition of the International Diabetes Federation. The baseline clinical evaluation included a clinical examination and evaluation of the blood levels of C-reactive protein, ghrelin, resistin, and fasting glucose. Within 72 h after the STEMI, an echocardiographic examination was performed. A complete clinical evaluation was repeated after 12 months. Adverse cardiac remodeling was defined as an increase in the left ventricular end-diastolic volume of ≥ 8%. An improvement of the ejection fraction (EF) was defined as an increase of more than 5% in the EF.

Results: A concentration of ghrelin ≤ 160.46 pg/ml (AUC = 0.71, = 0.032) had a good predictive value for the occurrence of adverse left ventricular remodeling but only in the patients without MeS. Among the patients with MeS, a concentration of resistin ≤ 5196 pg/ml (AUC = 0.073, = 0.024) had a good predictive value for the occurrence of left ventricular remodeling. A concentration of leptin > 52.18 pg/ml (AUC = 0.81, < 0.0001) and resistin > 4419.27 ng/ml (AUC = 0.67, = 0.049) had a good predictive value for improvement of the LVEF in the patients without MeS.

Conclusions: The selected adipokines had a good predictive value for the development of adverse cardiac remodeling and for improvement of the ejection fraction among patients after a STEMI in the presence of metabolic syndrome.

Citing Articles

IL-6, IL-1RA and Resistin as Predictors of Left Ventricular Remodelling and Major Adverse Cardiac Events in Patients with Acute ST Elevation Myocardial Infarction.

Scarlatescu A, Micheu M, Popa-Fotea N, Pascal A, Mihail A, Petre I Diagnostics (Basel). 2022; 12(2).

PMID: 35204357 PMC: 8871243. DOI: 10.3390/diagnostics12020266.

Fibroblast growth factor 21 levels and liver inflammatory biomarkers in obese subjects after weight loss.

Cantero I, Abete I, Bullon-Vela V, Crujeiras A, Casanueva F, Zulet M Arch Med Sci. 2022; 18(1):36-44.

PMID: 35154523 PMC: 8826683. DOI: 10.5114/aoms/98948.

Association between metabolic syndrome and psoriasis: a meta-analysis of observational studies with non-psoriasis control groups.

Qiao J, Jia Q, Jin H Arch Med Sci. 2021; 17(6):1558-1565.

PMID: 34900034 PMC: 8641498. DOI: 10.5114/aoms.2020.92434.

Association of Adiponectin, Leptin and Resistin Plasma Concentrations with Echocardiographic Parameters in Patients with Coronary Artery Disease.

Puchalowicz K, Kloda K, Dziedziejko V, Rac M, Wojtarowicz A, Chlubek D Diagnostics (Basel). 2021; 11(10).

PMID: 34679472 PMC: 8534895. DOI: 10.3390/diagnostics11101774.

The association between serum uric acid and features of metabolic disturbances in young adults.

Placzkowska S, Pawlik-Sobecka L, Kokot I, Piwowar A Arch Med Sci. 2021; 17(5):1277-1285.

PMID: 34522256 PMC: 8425241. DOI: 10.5114/aoms.2020.93653.

References

Paolisso G, Tagliamonte M, Galderisi M, Zito G, Petrocelli A, Carella C . Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension. 1999; 34(5):1047-52. DOI: 10.1161/01.hyp.34.5.1047. View

Fain J, Cheema P, Bahouth S, Hiler M . Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun. 2003; 300(3):674-8. DOI: 10.1016/s0006-291x(02)02864-4. View

Banerjee R, Lazar M . Resistin: molecular history and prognosis. J Mol Med (Berl). 2003; 81(4):218-26. DOI: 10.1007/s00109-003-0428-9. View

Barouch L, Cappola T, Harrison R, Crone J, Rodriguez E, Burnett A . Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. J Mol Cell Cardiol. 2003; 35(6):637-44. DOI: 10.1016/s0022-2828(03)00079-8. View

Sader S, Nian M, Liu P . Leptin: a novel link between obesity, diabetes, cardiovascular risk, and ventricular hypertrophy. Circulation. 2003; 108(6):644-6. DOI: 10.1161/01.CIR.0000081427.01306.7D. View

Hintz K, Aberle N, Ren J . Insulin resistance induces hyperleptinemia, cardiac contractile dysfunction but not cardiac leptin resistance in ventricular myocytes. Int J Obes Relat Metab Disord. 2003; 27(10):1196-203. DOI: 10.1038/sj.ijo.0802389. View

Pemberton C, Wimalasena P, Yandle T, Soule S, Richards M . C-terminal pro-ghrelin peptides are present in the human circulation. Biochem Biophys Res Commun. 2003; 310(2):567-73. DOI: 10.1016/j.bbrc.2003.09.045. View

Satoh H, Audrey Nguyen M, Miles P, Imamura T, Usui I, Olefsky J . Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest. 2004; 114(2):224-31. PMC: 449745. DOI: 10.1172/JCI20785. View

Kasper E, Hruban R, Baughman K . Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992; 70(9):921-4. DOI: 10.1016/0002-9149(92)90739-l. View

10.

Sato N, Kobayashi K, Inoguchi T, Sonoda N, Imamura M, Sekiguchi N . Adenovirus-mediated high expression of resistin causes dyslipidemia in mice. Endocrinology. 2004; 146(1):273-9. DOI: 10.1210/en.2004-0985. View

11.

le Roux C, Patterson M, Vincent R, Hunt C, Ghatei M, Bloom S . Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab. 2004; 90(2):1068-71. DOI: 10.1210/jc.2004-1216. View

12.

Barouch L, Gao D, Chen L, Miller K, Xu W, Phan A . Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ Res. 2005; 98(1):119-24. DOI: 10.1161/01.RES.0000199348.10580.1d. View

13.

Nikolsky E, Stone G, Grines C, Cox D, Garcia E, Tcheng J . Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. Am Heart J. 2005; 151(1):168-75. DOI: 10.1016/j.ahj.2005.03.024. View

14.

Morawietz H, Bornstein S . Leptin, endothelin, NADPH oxidase, and heart failure. Hypertension. 2006; 47(5):e20. DOI: 10.1161/01.HYP.0000218452.18010.fb. View

15.

Lubos E, Messow C, Schnabel R, Rupprecht H, Espinola-Klein C, Bickel C . Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis. 2006; 193(1):121-8. DOI: 10.1016/j.atherosclerosis.2006.05.039. View

16.

Smith C, Mocanu M, Davidson S, WYNNE A, Simpkin J, Yellon D . Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol. 2006; 149(1):5-13. PMC: 1629412. DOI: 10.1038/sj.bjp.0706834. View

17.

Gami A, Witt B, Howard D, Erwin P, Gami L, Somers V . Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007; 49(4):403-14. DOI: 10.1016/j.jacc.2006.09.032. View

18.

Navarro J, Redon J, Cea-Calvo L, Lozano J, Fernandez-Perez C, Bonet A . Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERIC-HTA study. Blood Press. 2007; 16(1):20-7. DOI: 10.1080/08037050701217817. View

19.

Gao J, Chua C, Chen Z, Wang H, Xu X, Hamdy R . Resistin, an adipocytokine, offers protection against acute myocardial infarction. J Mol Cell Cardiol. 2007; 43(5):601-9. PMC: 2692307. DOI: 10.1016/j.yjmcc.2007.08.009. View

20.

Soeki T, Kishimoto I, Schwenke D, Tokudome T, Horio T, Yoshida M . Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol. 2007; 294(1):H426-32. DOI: 10.1152/ajpheart.00643.2007. View